This article is more than 5 years old. Information may no longer be current.

Study: Iontophoretic corticosteroid treatment matches standard-of-care response in anterior uveitis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Patients with anterior uveitis who received two iontophoretic treatments of a corticosteroid formulation demonstrated a response rate that matched the current standard of care of multiple prednisolone acetate eye drops, according to a news release from EyeGate Pharma.

The randomized, double-masked placebo-controlled phase 3 study involved 193 patients at 45 clinical sites in the United States.

Of the 96 patients treated with two iontophoretic treatments of EGP-437 on days 0 and 7, 32 met the primary efficacy endpoint of anterior chamber cell count of 0 on day 14. Of the 97 patients treated with multiple daily self-administered eye drops of prednisolone acetate 1% ophthalmic suspension administered over 14 days, 32 met the primary efficacy endpoint.

The groups had comparable rates of severity and incidence of adverse events, the release said. The EGP-437 group had fewer incidences of elevated IOP.

While the current treatment requires as many as 16 daily eye drops for up to 6 weeks, the two iontophoretic treatments are more convenient, simple and reliable for patients, Stephen From, EyeGate Pharma president and CEO, said in the release.